Want to join the conversation?
$CELG President Jacqualyn Fouse said that the company expects 2016 Revlimid sales to grow to $6.6-6.7Bil, up 15% at the mid point of the range driven by volume. Pomalyst/Imnovid and Abraxane are both expected to officially reach blockbuster drug status in 2016 by each surpassing the $1Bil revenue mark.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.